Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
07 déc. 2017 16h05 HE
|
Cascadian Therapeutics, Inc.
SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of...